氧流辅助局部外用甲氨蝶呤治疗浅表皮肤肿瘤的探索性评估
本研究为初步试验,评估氧流辅助LP3载体中3%甲氨蝶呤(LP3-MTX3%)外用治疗浅表性基底细胞癌(n=12)、乳房外Paget病(n=5)、经典蕈样肉芽肿(MF;n=10)和毛囊性MF(n=6)的疗效、安全性与耐受性,每周4次涂抹,治疗前后行照片与活检。治疗后1个月,各组临床评分分别改善77.5%±17.1%(P<0.0001)、66.7%±22.9%(P=0.011)、51.3%±32.2%(P=0.0007)和27.8%±32.0%(P=0.086);耐受性良好,无疼痛,血清中始终未检出MTX。
要点
- 氧流辅助LP3-MTX3%外用对浅表性基底细胞癌、乳房外Paget病和MF显示治疗作用
- 治疗后1个月组织学见部分或完全清除,毛囊性MF未见完全清除
- 治疗耐受性良好、无疼痛,各时间点血清MTX均未检出
核心结论
- 氧流辅助LP3-MTX3%外用对浅表性基底细胞癌、乳房外Paget病和MF病变显示出值得关注的疗效,值得扩大规模进一步研究。
研究设计与样本
- 初步试验,纳入浅表性基底细胞癌12例、乳房外Paget病5例、经典MF10例和毛囊性MF6例,每周4次外用氧流辅助LP3-MTX3%,治疗前后行照片与活检。
主要发现
- 治疗后1个月,浅表性基底细胞癌红斑-结痂-厚度临床评分平均改善77.5%±17.1%(P<0.0001)。
- 乳房外Paget病红斑-渗液-鳞屑/角化过度-疼痛/瘙痒临床评分平均改善66.7%±22.9%(P=0.011)。
- 经典MF改良复合病灶严重度评分平均改善51.3%±32.2%(P=0.0007),毛囊性MF平均改善27.8%±32.0%(P=0.086)。
- 治疗后1个月组织学部分与完全清除:浅表性基底细胞癌1/12与11/12,乳房外Paget病4/5与1/5,经典MF8/10与2/10,毛囊性MF6/6与0/6。
- 耐受性良好、无疼痛,基线及治疗后1、2、3、8、24、48、72小时血清MTX均未检出。
临床怎么用
- 结果提示氧流辅助LP3-MTX3%外用可能作为浅表性基底细胞癌、乳房外Paget病和MF的探索性局部治疗选择。
局限性
- 为初步试验,样本量小,需扩大规模进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The molecular weight of methotrexate (MTX) makes cutaneous penetration difficult. Oxygen flow could enhance the skin permeation of MTX diluted in the proprietary LP3 carrier system. This pilot study aims to assess the efficacy, safety, and tolerance of oxygen flow-assisted LP3-MTX3% for treating superficial skin cancers. Patients with superficial basal cell carcinoma (n = 12), extramammary Paget disease (n = 5), classic mycosis fungoides (MF; n = 10), and folliculotropic MF (n = 6) were included in the study and were treated with four weekly applications of oxygen flow-assisted LP3-MTX3%. Photographs and biopsies were performed before and one month after treatment. At one month after treatment, the mean superficial basal cell carcinoma erythema-crusting-thickness clinical score, the extramammary Paget disease erythema-oozing-scaling/hyperkeratosis-pain/pruritus clinical score, and the modified composite assessment of index lesion severity classic MF and folliculotropic MF scores were improved by 77.5% ± 17.1% (P < 0.0001), 66.7% ± 22.9% (P = 0.011), 51.3% ± 32.2% (P = 0.0007), and 27.8% ± 32.0% (P = 0.086), respectively. At one month after treatment, histology revealed partial and total clearances for superficial basal cell carcinoma (1/12, 11/12), extramammary Paget disease (4/5, 1/5), classic MF (8/10, 2/10), and folliculotropic MF (6/6, 0/6). Tolerance was excellent and no pain was observed. MTX was never detectable in serum at baseline and 1, 2, 3, 8, 24, 48, and 72 hours post-treatment. In conclusion, the interesting therapeutic efficacy of oxygen flow-assisted LP3-MTX3% for treating superficial basal cell carcinoma, extramammary Paget disease, and MF lesions prompts further studies on a larger scale.
引用
- Lebas E, Chapelier C, Quatresooz P, et al. Exploratory Assessment of Oxygen Flow-Assisted Cutaneous Administration of Methotrexate for Superficial Basal Cell Carcinoma, Mycosis Fungoides, and Extramammary Paget Disease. J Invest Dermatol. 2019. PMID: 31513804. doi:10.1016/j.jid.2019.08.443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。